{"title":"Meet the Editorial Board Member","authors":"A. Carella","doi":"10.2174/1871529x2104211231145446","DOIUrl":null,"url":null,"abstract":"Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529x2104211231145446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.